Analysts Are Bullish on Sarepta Therapeutics

Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in the first quarter. The company’s revenue rose 100% YoY as compared to $16.3 million in the first quarter of 2017. Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017.

The above chart compares analysts’ recommendations over the last 12 months.

Sarepta’s stock price has risen ~216.1% over the last 12 months and ~118.8% in 2018 year-to-date. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. Analysts have a 12-month target price of $184.53 per share as compared to the last price of $120.87 per share as of August 3.

As of August 6, 19 analysts were tracking Sarepta Therapeutics stock. Of these, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” one analyst recommended a “hold,” and none of the analysts recommended a “sell.” The consensus rating for Sarepta’s stock is 1.74, which represents a “strong buy” for momentum investors and long-term investors.

The Invesco Dynamic Biotechnology & Genome ETF (PBE) holds 3.2% of its total investments in Sarepta Therapeutics (SRPT), 4.6% in Alexion Pharmaceuticals (ALXN), 4.8% in Vertex Pharmaceuticals (VRTX), and 5.2% in Biogen (BIIB).